Gland Pharma gets one 483 Observation from USFDA for Dundigal facility

Published On 2023-07-14 07:59 GMT   |   Update On 2023-07-14 07:59 GMT
Advertisement

HyderabadGland Pharma today announced that the United States Food and Drug Administration (USFDA) has issued one 483 Observation at the conclusion of the Good Manufacturing Practice (GMP) inspection at the Company's Dundigal Facility at Hyderabad.

The inspection was conducted between 03rd July, 2023 and 14th July, 2023.

"The corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity," the company stated in a BSE filing.

Advertisement

Medical Dilaogues team had earlier reported that the company had received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, USFDA indicating closure of the inspection at the company's Dundigal Facility.

Read also: Gland Pharma gets UFSDA EIR for Dundigal Facility

Gland Pharma, a generic injectable-focused pharmaceutical company was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News